ECOG-ACRIN NCORP Research Base

项目摘要 ECOG-ACRIN癌症研究小组（EA）致力于降低癌症负担。EA 是国家临床试验网络（NCTN）和NCI社区肿瘤学的活跃成员 研究计划（NCORP），专注于改变实践的临床和转化研究， 癌症护理的连续性，从预防和早期发现，通过先进的管理， 疾病及其影响。作为NCORP研究基地，EA已经与社区提供商合作， 研究人员开发一个强大的研究组合，涵盖癌症预防，癌症控制， 癌症护理交付，与精确肿瘤学，免疫肿瘤学， 减少过度诊断和过度治疗，并利用新的生物标志物平台。癌症控制 试验检查并干预与癌症和治疗相关症状相关的挑战， 性问题EA的治疗试验组合为应用患者报告的结果提供了机会 测量科学，以量化与健康相关的生活质量，症状和最相关的领域， 患者在不断发展的治疗模式的背景下。行为和生物标志物驱动症状 干预措施旨在提高生活质量和癌症存活率。毒理学研究旨在 通过量化与治疗相关的心脏毒性，识别风险人群， 加强干预措施，降低风险。预防试验采用NCI对预防的广泛定义 包括一级预防、癌症筛查和二级预防，旨在识别高风险 精准预防战略。癌症护理交付研究（CCDR）检查了 患者、提供者和影响护理的系统因素之间的复杂相互作用， 评估异质性社区肿瘤学实践中的干预措施。健康公平研究 通过嵌入与EA活动相关的研究问题来渗透EA科学， 对得不到充分服务的人口，包括青少年和年轻人、老年人， 种族和族裔少数群体、性和性别少数群体以及农村居民。主要合作伙伴 基于社区的肿瘤学项目将确保社区获得EA NCTN和NCORP试验 病人接受治疗的地方EA提供对现有NCI资助资源和网络的访问 >10000名医生、科学家、护士、研究助理（RA）、统计学家、生物医学信息 技术专家和患者倡导者在大约600个机构和组织。EA已经 通过推进严格的，改变实践的， 在癌症控制、预防和护理方面的临床试验和转化研究， 继续支持NCI的使命，让社区的不同人群参与癌症治疗 research.

Project Summary The ECOG-ACRIN Cancer Research Group (EA) is dedicated to decreasing the burden of cancer. EA is a vibrant member of the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP), focused on practice-changing clinical and translational research across the cancer care continuum from prevention and early detection, through the management of advanced disease and its impact. As an NCORP Research Base, EA has engaged community providers and researchers to develop a robust research portfolio that spans Cancer Prevention, Cancer Control, and Cancer Care Delivery, aligned with the overall scientific themes of precision oncology, immuno-oncology, reducing overdiagnosis and overtreatment, and leveraging novel biomarker platforms. Cancer control trials examine and intervene on challenges associated with cancer and treatment-related symptoms and concerns. EA's portfolio of therapeutic trials yield opportunities to apply patient-reported outcomes measurement science to quantify health-related quality of life, symptoms, and domains most relevant to patients in the context of evolving treatment paradigms. Behavioral and biomarker-driven symptom interventions aim to improve quality of life and cancer survivorship. Cardiotoxicity research aims to mitigate risk through quantifying cardiotoxicity associated with treatment, identifying groups at risk, and advancing interventions to reduce risk. Prevention trials embrace the NCI's broad definition of prevention to include primary prevention, cancer screening, and secondary prevention and aim to identify high risk groups for precision prevention strategies. Cancer Care Delivery Research (CCDR) examines the complex interactions between patient, provider, and system factors that influence care, and adapts and evaluates interventions in heterogenous community oncology practices. Health equity research permeates EA science through embedding disparities-related research questions that span EA activities, adopting a broad view of underserved populations including adolescents and young adults, the elderly, racial and ethnic minorities, sexual and gender minorities and rural residents. Key collaborations with community-based oncology programs will ensure access to EA NCTN and NCORP trials in communities where patients receive their care. EA provides access to existing NCI-funded resources and a network of >10000 physicians, scientists, nurses, research associates (RAs), statisticians, biomedical information technologists, and patient advocates across approximately 600 institutions and organizations. EA has provided scientific leadership in the NCORP community through advancing rigorous, practice-changing clinical trials and translational research in cancer control, prevention and care delivery and is well poised to continue to support the NCI's mission to engage community-based diverse populations in cancer research.